Histone Deacetylase Inhibitors: A New Class of Potential Therapeutic Agents for Cancer Treatment: Commentary re: V. Sandor et al., Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res., 8: 718–728, 2002.

Victoria M. Richon,James P. O'Brien

Histone Deacetylase Inhibitors: A New Class of Potential Therapeutic Agents for Cancer Treatment: Commentary re: V. Sandor et al., Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res., 8: 718–728, 2002.

2002

Victoria M. Richon
James P. O'Brien

HDAC[2][1] inhibitors are members of a new class of agents that modulate the expression of genes by causing an increase in histone acetylation, thereby regulating chromatin structure and transcription [(1][2] [, 2)][3] . In this issue, Sandor et al. [(3)][4] describe the results of a Phase I study

Keywords:

Cancer research
Acetylation
Chromatin
Histone deacetylase inhibitor
Cancer
Depsipeptide
Histone deacetylase
Histone
Biology
cancer treatment
Transcription (biology)
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

137

Citations